Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report
Abstract
Traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) have previously been reported to be associated with increased risk of Alzheimer's disease (AD). We are using biomarkers to study Vietnam Veterans with/without mild cognitive impairment with a history of at least one TBI and/or ongoing PTSD to determine whether these contribute to the development of AD.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 12, 2017
- Source ID
- 10.1016/j.trci.2017.02.005
Entities
People
- Andrew J. Saykin
- Charles Decarli
- Clifford Jack
- Dallas P. Veitch
- Danielle Harvey
- Department Of Defense Alzheimer's Disease Neuroimaging Initiative
- Duygu Tosun
- Jacqueline Hayes
- Jordan Grafman
- Michael W. Weiner
- Paul S. Aisen
- Ronald C. Petersen
- Susan M. Landau
- Thomas C. Neylan
Organizations
- Abbott Laboratories
- AstraZeneca
- Avid Radiopharmaceuticals
- Bayer HealthCare
- BioClinica
- Eisai
- Eli Lilly and Company
- GE HealthCare
- GSK
- Geneva University Hospitals
- Helen Wills Neuroscience Institute
- Hoffmann-La Roche
- Indiana University
- Innogenetics
- Johnson & Johnson
- Loma Linda University Medical Center
- Mayo Clinic
- Medpace
- Merck & Co.
- National Institute on Aging
- National Institutes of Health
- National Science Foundation
- Northwestern University
- Novartis
- Perrigo Company Plc
- Pfizer
- Roche (United States)
- Siemens
- Sorbonne Paris North University
- Tohoku University
- United States Department of Defense
- United States Department of Veterans Affairs
- University of California
- University of California, Davis
- University of California, San Francisco
- University of Southern California
- Wyeth